Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Receivables data on record, last reported at $87.1 million in Q4 2025.

  • For Q4 2025, Receivables rose 81.25% year-over-year to $87.1 million; the TTM value through Dec 2025 reached $87.1 million, up 81.25%, while the annual FY2025 figure was $87.1 million, 81.25% up from the prior year.
  • Receivables reached $87.1 million in Q4 2025 per TARS's latest filing, up from $74.3 million in the prior quarter.
  • Across five years, Receivables topped out at $87.1 million in Q4 2025 and bottomed at $200000.0 in Q4 2021.
  • Average Receivables over 5 years is $28.4 million, with a median of $25.2 million recorded in 2021.
  • Peak YoY movement for Receivables: tumbled 99.0% in 2022, then surged 2862.79% in 2023.
  • A 5-year view of Receivables shows it stood at $200000.0 in 2021, then soared by 1691.0% to $3.6 million in 2022, then soared by 394.53% to $17.7 million in 2023, then surged by 171.31% to $48.1 million in 2024, then soared by 81.25% to $87.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $87.1 million in Q4 2025, $74.3 million in Q3 2025, and $60.2 million in Q2 2025.